The Health 202: This mother’s tweet about drug prices went viral. Trump’s plans are unlikely to help image

Washington Post, July 24, 2018
by Colby Itkowitz, quoting Rachel Sachs (Academic Fellow Alumna)


Read the full article

From the article:

“It’s going to take a lot of time and there's a lot of hurdles in the way, but that’s not what you want to explain when you want to show how you’re lowering drug prices,” he told me. “Ultimately they are going to have to be willing to upset some stakeholders including the pharmaceutical industry. The only way you know you’re really lowering prices is revenue is going to fall for these pharmaceutical companies.”

Gellad said Trump can probably take some credit for some drug companies halting price increases, but such action doesn't count as fundamental change to the drug market if companies are just temporarily reacting to presidential pressure. 

Rachel Sachs, a law professor with an expertise in drug policy at Washington University in St. Louis, largely agreed. 

Read more here!

fda health care finance health care reform health law policy pharmaceuticals public health rachel sachs